Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EBMT 2020 | The management & optimization of CAR T-cell therapy in myeloma

CAR T-cell therapy offers many opportunities, but also challenges. Michel Delforge, MD, PhD, University of Leuven, Leuven, Belgium, discusses the management and optimization of CAR T-cell therapy in multiple myeloma. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).